Φορτώνει......

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

PURPOSE: Up to 50% of patients with uveal melanoma (UM) develop metastatic disease with limited treatment options. The immunomodulating agent ipilimumab has shown an overall survival (OS) benefit in patients with cutaneous metastatic melanoma in two phase III trials. As patients with UM were exclude...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:PLoS One
Κύριοι συγγραφείς: Zimmer, Lisa, Vaubel, Julia, Mohr, Peter, Hauschild, Axel, Utikal, Jochen, Simon, Jan, Garbe, Claus, Herbst, Rudolf, Enk, Alexander, Kämpgen, Eckhart, Livingstone, Elisabeth, Bluhm, Leonie, Rompel, Rainer, Griewank, Klaus G., Fluck, Michael, Schilling, Bastian, Schadendorf, Dirk
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Public Library of Science 2015
Θέματα:
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4356548/
https://ncbi.nlm.nih.gov/pubmed/25761109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0118564
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!